By comparison to treatment with anti-PD-1 FcS alone, reductions in mean tumor volumes were statistically significant in mice receiving anti-PD-1 FcS combined with anti-GARP:TGF-β1 (WT or FcD), but not with anti-TGF-β (Fig. 2c). Here, TGFB1 is linked to neoplasm.